Markets:

Overview

News

Currencies

International

Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

9.770 +0.900 (+10.15%)

Streaming Delayed Price Updated: 1:16 PM EDT, Jun 3, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Analyst Ratings for Replimune Group ↗

June 07, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 05, 2023

Via Benzinga

Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

June 05, 2023

Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding.

Via Benzinga

Replimune Group Inc. (NASDAQ: REPL) Making Surprising Moves in Monday Session

June 05, 2023

Via Investor Brand Network

Recap: Replimune Group Q4 Earnings ↗

May 18, 2023

Via Benzinga

Analyst Ratings for Replimune Group ↗

December 07, 2022

Via Benzinga

Replimune Group: Q2 Earnings Insights ↗

November 03, 2022

Replimune Group (NASDAQ:REPL) reported its Q2 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes ↗

June 05, 2023

ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference.

Via Investor's Business Daily

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗

April 13, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform ↗

December 12, 2022

Last Thursday, Replimune Group Inc (NASDAQ: REPL) announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical.

Via Benzinga

PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday ↗

December 12, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

December 07, 2022

Via Benzinga

Analyst Ratings for Replimune Group ↗

May 24, 2022

Analysts have provided the following ratings for Replimune Group (NASDAQ:REPL) within the last quarter:

Via Benzinga

Replimune Group: Q3 Earnings Insights ↗

February 03, 2022

Replimune Group (NASDAQ:REPL) reported its Q3 earnings results on Thursday, February 3, 2022 at 08:00 AM.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session ↗

December 07, 2022

Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC...

Via Benzinga

Replimune Shares Surge After Early Data From Pretreated Melanoma Patients ↗

December 07, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

December 07, 2022

Via Benzinga

Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts ↗

October 14, 2022

Via Benzinga

Wells Fargo To Surge Around 20%? Here Are 5 Other Price Target Changes For Monday ↗

October 03, 2022

Goldman Sachs raised Wells Fargo & Company (NYSE: WFC) price target from $46 to $48. Goldman Sachs analyst Richard Ramsden upgraded the stock from Neutral to Buy. Wells Fargo shares rose 1.1% to $40.68...

Via Benzinga

PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst ↗

May 25, 2022

Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than...

Via Benzinga

Replimune Group: Q4 Earnings Insights ↗

May 19, 2022

Replimune Group (NASDAQ:REPL) reported its Q4 earnings results on Thursday, May 19, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Replimune Group missed...

Via Benzinga

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗

March 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program ↗

February 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 18, 2022

On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

January 20, 2022

During Thursday's morning trading, 152 companies set new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Rivian Automotive (NASDAQ:RIVN) was the largest...

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

August 23, 2021

Telsey Advisory Group boosted the price target for Burlington Stores, Inc. (NYSE:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗

November 08, 2021

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.